Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennie H Best

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Rheumatology and Therapy|October 18, 2016
Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional SurveyDana B DiBenedetti, Xiaolei Zhou, Maria Reynolds, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 11, 2005
Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphomaJennie H Best, John Hornberger, Stephen J Proctor, et al.
Journal of Medical Economics|July 17, 2012
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the USYevgeniy Samyshkin, Anne-Laure Guillermin, Jennie H Best, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 11, 2020
Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell ArteritisJennie H Best, Amanda M Kong, David M Smith, et al.
Cardiovascular Diabetology|March 26, 2013
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goalsAlison R Meloni, Mary Beth DeYoung, Jenny Han, et al.
The Annals of Pharmacotherapy|February 6, 2014
Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargineManjiri Pawaskar, Katherine R Tuttle, Qian Li, et al.
Journal of Medical Economics|April 27, 2012
Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysisElise M Pelletier, Manjiri Pawaskar, Paula J Smith, et al.
Rheumatology and Therapy|January 14, 2017
Estimating the Cost of Illness of Giant Cell Arteritis in the United StatesJoseph B Babigumira, Meng Li, Denise M Boudreau, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 20, 2010
Preference values associated with stage III colon cancer and adjuvant chemotherapyJennie H Best, Louis P Garrison, William Hollingworth, et al.
BMJ Open|June 17, 2021
Association of biological antirheumatic therapy with risk for type 2 diabetes: a retrospective cohort study in incident rheumatoid arthritisSanjoy K Paul, Olga Montvida, Jennie H Best, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Rheumatology and Therapy|October 18, 2016
Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional SurveyDana B DiBenedetti, Xiaolei Zhou, Maria Reynolds, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 11, 2005
Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphomaJennie H Best, John Hornberger, Stephen J Proctor, et al.
Journal of Medical Economics|July 17, 2012
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the USYevgeniy Samyshkin, Anne-Laure Guillermin, Jennie H Best, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 11, 2020
Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell ArteritisJennie H Best, Amanda M Kong, David M Smith, et al.
Cardiovascular Diabetology|March 26, 2013
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goalsAlison R Meloni, Mary Beth DeYoung, Jenny Han, et al.
The Annals of Pharmacotherapy|February 6, 2014
Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargineManjiri Pawaskar, Katherine R Tuttle, Qian Li, et al.
Journal of Medical Economics|April 27, 2012
Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysisElise M Pelletier, Manjiri Pawaskar, Paula J Smith, et al.
Rheumatology and Therapy|January 14, 2017
Estimating the Cost of Illness of Giant Cell Arteritis in the United StatesJoseph B Babigumira, Meng Li, Denise M Boudreau, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 20, 2010
Preference values associated with stage III colon cancer and adjuvant chemotherapyJennie H Best, Louis P Garrison, William Hollingworth, et al.
BMJ Open|June 17, 2021
Association of biological antirheumatic therapy with risk for type 2 diabetes: a retrospective cohort study in incident rheumatoid arthritisSanjoy K Paul, Olga Montvida, Jennie H Best, et al.
Pageof 4